Everything drug pricing and policy, every day
And a Health Affairs paper explains how 340B hospitals in 27 states can siphon savings that would otherwise accrue to state Medicaid programs
And how one pharmaceutical company expects to see revenue spike ... by slashing the list price of its medicine
The Jan. 1 pricing decisions for the 10 best-selling medicines might surprise you
And a critical 2026 trend -- dropping list prices on blockbuster drugs -- has begun with a 40%+ cut to Imbruvica’s price
And the results of the “Nobody Knows” Prediction Contest
Plus, a rosy AARP survey suggests that Medicare “negotiations” will lower out-of-pocket costs. The truth is likely to be more complicated.
And introducing the first annual ‘Nobody Knows’ Prediction Contest
And Pfizer’s take on the pharm-to-table opportunity in obesity: ‘Multiples of what we were expecting’
